Slayback Pharma has launched its genital herpes ointment Generic Zovirax Ointment (Acyclovir Ointment) 5% in the US.
The launch of the genital herpes ointment was done through its out-licensee – Sandoz (Fougera), a generic drug subsidiary of Novartis, which holds the sales and marketing rights of the Slayback product.
Sandoz secured the Abbreviated New Drug Application (ANDA) in the US for Generic Zovirax Ointment (Acyclovir Ointment) 5% in May this year.
Slayback Pharma CEO Ajay K Singh said: “Slayback’s core focus is the development of complex generics primarily in parenteral and other non-solid pharmaceutical products by connecting the dots across various technologies, science, regulatory and intellectual property traditions.
“The successful development and approval of a complex generic formulation of Acyclovir Ointment meeting FDA’s standards is a testimony to this effort.”
A generic version of Zovirax Ointment (Acyclovir Ointment) from Valeant Pharmaceuticals, Zovirax Ointment (Acyclovir Ointment) 5% has been advised for treating genital herpes. It has also been indicated in the management of limited non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients.
Acyclovir Ointment has been advised not to be used to treat patients who develop intolerance to the formulation components.
It is also advised to be used only on the affected skin area and should not come in contact with the eye.
Terms of the agreement between Slayback Pharma and Sandoz have not been remained.
However, Sandoz like before will pay Slayback Pharma, its share of the profits coming from the sale of genital herpes ointment Generic Zovirax Ointment (Acyclovir Ointment) 5% in the US.
Genital herpes is a sexually transmitted disease caused by caused by the herpes simplex virus (HSV) which has affected at least 50 million people in the US, as per Webmd. This chronic, viral infection that stays lifelong affects the genitals, buttocks and/or the anal area.
Genetic herpes patients are at double risk of contracting HIV infection.